Skip to content

EndoGastric Solutions > Results of EsophyX Multi-Center GERD Study > Transoral incisionless fundoplication surgery > No skin incisions > No cutting of vessels > No dissection of the fundus > 85% of patients remain symptom-free > Off daily GERD medication > Chanbe the dependence on pharmaceuticals

Are the effects of daily GERD medication raising concerns that there are additional detrimental effects of pharmaceuticals that should be avoided? Is EsophyX a technology that advances the treatment of GERD forward? Is the discontinue of GERD medications especially important for women in the face of osteoporosis?

esophyx.jpg

IIP > Read on here…

EndoGastric Solutions, the world leader in natural orifice surgery products and procedures, announces outstanding results at the completion of 1-year follow-up on GERD patients in the phase 2 multi-center study of the first generation transoral incisionless fundoplication (TIF 1) procedure and first-generation EsophyX device. EndoGastric Solutions is the first company to successfully design truly incisionless transoral surgical products that mimic the outcomes of the more invasive gold-standard antireflux surgeries, laparoscopic fundoplications (i.e. Nissen, Toupet or Hill procedures). The EsophyX device enables surgeons and advanced interventional gastroenterologists to offer their patients substantive anatomical repair without incisions (no skin or internal dissection) for front-line surgical management of gastroesophageal reflux disease (GERD) patients…

Dr. Todd Overcash, Medical Director of Bariatric and Minimally Invasive Surgery at Munroe Regional Medical Center in Ocala, Florida, is the United States leader of NOS (Natural Orifice Surgery) procedures performed. He was among the first U.S. surgical teams that went to Europe last fall to train in this new technique…

Post a Comment

You must be logged in to post a comment.